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non-canonical IL6 signaling through gp130
Xinlei Wang1,2, Eric B. Miller3, Mayank Goswami2,4, Pengfei Zhang2,4, Kaitryn E. Ronning3, Sarah J. Karlen3,4,
Robert J. Zawadzki1,2, Edward N. Pugh Jr.2,4 and Marie E. Burns1,3,4*Abstract
Background: Retinal detachment (RD) can lead to proliferative vitreoretinopathy (PVR), a leading cause of
intractable vision loss. PVR is associated with a cytokine storm involving common proinflammatory molecules like
IL6, but little is known about the source and downstream signaling of IL6 and the consequences for the retina.
Here, we investigated the early immune response and resultant cytokine signaling following RD in mice.
Methods: RD was induced in C57BL/6 J and IL6 knockout mice, and the resulting inflammatory response was
examined using immunohistochemistry and flow cytometry. Cytokines and signaling proteins of vitreous and
retinas were quantified by multiple cytokine arrays and Western blotting. To attempt to block IL6 signaling, a
neutralizing antibody of IL6 receptor α (IL6Rα) or IL6 receptor β (gp-130) was injected intravitreally immediately
after RD.
Results: Within one day of RD, bone marrow-derived Cd11b +monocytes had extravasated from the vasculature
and lined the vitreal surface of the retina, while the microglia, the resident macrophages of the retina, were
relatively unperturbed. Cytokine arrays and Western blot analysis revealed that this sterile inflammation did not
cause activation of IL6 signaling in the neurosensory retina, but rather only in the vitreous and aqueous humor.
Monocyte infiltration was inhibited by blocking gp130, but not by IL6 knockout or IL6Rα blockade.
Conclusions: Together, our results demonstrate that monocytes are the primary immune cell mediating the
cytokine storm following RD, and that any resulting retinal damage is unlikely to be a direct result of retinal IL6
signaling, but rather gp130-mediated signaling in the monocytes themselves. These results suggest that RD should
be treated immediately, and that gp130-directed therapies may prevent PVR and promote retinal healing.
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InflammationBackground
Retinal detachment (RD) refers to separation of the neu-
rosensory retina from the underlying retinal pigment
epithelium (RPE) in the posterior eye. RD occurs spon-
taneously with a prevalence of 1–2.2 in 10,000 [1–4],
and much more frequently in elderly patients after cata-
ract surgery (0.99%) and in high myopia populations [5].* Correspondence: meburns@ucdavis.edu
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(http://creativecommons.org/publicdomain/zePrompt surgical procedures are required to save vision,
but are often delayed for the convenience of both patient
and practitioner. In many countries, this delay exceeds
several weeks [6]. Delayed treatment often leads to ser-
ious secondary complications, including proliferative
vitreoretinopathy (PVR). PVR is caused by proliferation
of glial or RPE cells to form a fibrous, multicellular scar
termed epiretinal membrane at the retinal surface. The
epiretinal membrane can produce physical traction and
deformation of the retina, leading to more widespread
detachment, tears, and retinal puckers. Because PVR
often leads to poor visual outcomes, understanding howle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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of utmost importance.
PVR is triggered by a cytokine storm, including MCP-
1/CCL2 [7], IL6 [7–9], ICAM-1 [8], and TIMP-1 [9].
One common pro-inflammatory cytokine implicated in
PVR, as well as the acute phase response of many in-
flammatory diseases, is interleukin 6 (IL6). Secreted by
T cells, dendritic cells and macrophages, IL6 is signifi-
cantly elevated in the vitreous [9, 10], aqueous humor
[7] and subretinal fluid [7–9] of PVR patients in a man-
ner correlated with the extent of the RD [9]. IL6 recep-
tors consist of subunit α (IL6Rα) and subunit β (gp130,
also known as IL6Rβ and CD130), a signal transducer
also shared by many other cytokines. IL6Rα is a plasma
membrane protein expressed by hepatocytes and some
leukocytes, though a soluble form of IL6Rα (sIL6Rα)
comprising the extracellular portion of the receptor can
bind IL6 with a similar affinity. Both humanized IL6-
specific mAb and IL6Rα-specific mAb, which target
IL6 and sIL6Rα respectively, have been shown to be
effective in treating rheumatoid arthritis and experi-
mental colitis [11].
In the present study, we investigate the acute in-
flammation triggered by RD, and test the role of IL6
signaling in its initiation and resolution. These find-
ings have important implications for treatment of RD
in humans, and may motivate future scientific re-
search on cytokine-specific antibody development for
preventing PVR.
Methods
Animals and study design
All animals were handled in accordance with NIH guide-
lines for the care and use of experimental animals and
approved protocol by the Institutional Animal Care and
Use Committee of the University of California, Davis.
Adult (8-week-old) C57BL/6 J mice and IL6 knockout
(KO) mice were purchased from Jackson Laboratory
(stocks 000664, 002650). For ocular injections and
in vivo imaging, mice were anesthetized with 1-4% iso-
flurane, and the pupils dilated with 1% tropicamide and
2.5% phenylephrine ophthalmic solution. Lubricant eye
gel (GenTeal) was used to maintain corneal hydration
during the procedures. For tissue collection, mice were
euthanized by CO2 narcosis.
Mice were randomized into 5 groups for analysis: (1)
Normal control with no ocular perturbations (2) RD in
both eyes with no treatment; (3) RD with intravitreal in-
jection of anti-IL6Rα antibody in both eyes; (3) RD with
intravitreal injection of anti-gp130 antibody in both
eyes and (4) RD with intravitreal injection of IgG1
isotype control or PBS in both eyes; (5) IL6 KO mice
were induced RD without any treatment or intravit-
real injection.Subretinal and intravitreal Injection
A previous method [12] for inducing bullous and per-
manent RD was modified to avoid any retinal holes and
subretinal hemorrhage. Briefly, a superior scleral hole
was gently made with the bevel of 30 G insulin syringe
needle (BD Ultra-Fine™), avoiding any retinal damage.
Anterior chamber puncture was made to relieve any ele-
vation of intraocular pressure. A 33 G needle connected
to Hamilton 2.5 μl syringe was inserted into the scleral
hole and carefully positioned within the subretinal space.
Sodium hyaluronate (2 μl, ProVisc, Alcon) was gently
injected to detach the neurosensory retina from RPE. In
the treated groups, 2 μl of polyclonal goat anti-mouse
IL6Rα IgG antibody (R&D system, AF1830) or monoclo-
nal rat anti-mouse gp130 IgG1 antibody (R&D system,
MAB4682) or monoclonal mouse IgG1 isotype control
(R&D system, MAB002) or PBS was injected into the
vitreous cavity following detachment. The success of
hemi-retinal detachment was confirmed by visual micro-
scopic inspection, and in a subset of cases, OCT im-
aging. Mice with detachments that were accompanied by
retinal holes, subretinal or vitreous hemorrhage were ex-
cluded from subsequent studies. More details about
anti-IL6Rα and anti-gp130antibodies used in the current
study are given in Additional file 1: Table S1.
OCT imaging
OCT imaging was performed using a custom imaging
system as previously described [13]. OCT volumes con-
sisting of 100 B-scans (2000 A-scans/B-scan) spanning ∼
1.6 mm × 1.6 mm at the retina (32 μm/deg) were used to
quantify changes associated with retinal detachment. Six
consecutive B-scans were averaged to reduce the speckle
noise in the image, corresponding to lateral averaging
over 80 μm. Retinal thickness was extracted using semi-
automated segmentation software utilizing support vec-
tor machine [14].
Aqueous humor, vitreous and retina collection
After euthanasia, eyes were removed from the orbit. A
limbus incision was made with the bevel of 30G needle,
then the tip of a 2.5 μl pipette was inserted into the vit-
reous cavity to collect aqueous and vitreous humor (typ-
ically, 3–5 μl from each eye). Anterior segments were
removed and discarded, and retinas were separated from
the RPE. Retina and vitreous samples were snap frozen
in liquid nitrogen and stored in −80 °C for further use.
Immunohistochemistry
Eyes were fixed in 4% paraformaldehyde in PBS for
5 min at room temperature. The cornea and lens were
then removed with the vitreous still attached. The eye-
cups were fixed for another 20 min, and then dehydrated
with 30% sucrose at 4 °C overnight. Eyecups were
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−20 °C, then sectioned through the optic nerve at a
thickness of 20 μm in the sagittal plane using Microm
HM 550 cryostat (Thermo Scientific). For retinal flat
mounts, nasal-temporal cuts were made along the two
large vessels at the posterior surface for orientation and
relaxing cuts were made to divide the inferior retina into
three quadrants. Tissue was incubated with 1% Triton
X-100 for 30 min at room temperature, and blocked
with 1.5% BSA (bovine serum albumin, A7030, Sigma-
Aldrich) at 37 °C for 60 min. Tissue was then incubated
with rabbit anti-Iba1 (1:100, Wako) and rat anti-mouse
CD11b (1:100, eBioscience) overnight at 4 °C. Secondary
staining with Alexa 488-conjugated goat anti-rabbit and
Alexa 633-conjugated goat anti-rat antibodies (both
1:300, Invitrogen Life Technologies) was performed at
37 °C for 60 min. Tissue was mounted with ProLong
gold antifade reagent (Invitrogen Life Technologies) and
imaged using a Nikon Ti-E A1 multiphoton imaging sys-
tem. More details about the anti-IL6Rα antibodies and
anti-gp130 antibody used for supplementary immuno-
histochemistry experiments were shown in Additional
file 1: Table S1.
Flow cytometry
Cells were harvested and counted as described previ-
ously [15] with some modifications. Briefly, two retinas
were minced in 1 ml of Hank’s Balanced Salt Solution
(Thermo Fisher Scientific) containing 2 mg/ml Collage-
nase D and 28 U/ml DNase I (both from Sigma-
Aldrich). Tissue was incubated at 37 °C for 60 min, and
re-suspended in 2 ml of Hibernate media (Thermo
Fisher Scientific). The suspension was filtered through a
140 μm-mesh screen (Sigma-Aldrich), washed, and cen-
trifuged; supernatant was carefully removed. Cell pellets
were fixed and permeabilized for 10 min at RT in 4%
paraformaldehyde/0.1% saponin buffer (Sigma-Aldrich),
then blocked for 15 min at RT in 3% BSA. Cells were in-
cubated in Alexa Fluor 647 conjugated anti-mouse
CD11b antibody (1:100, Biolegend, USA) and Alexa
Fluor 488 conjugated IB4 (1:100, Thermo Fisher Scien-
tific) overnight at 4 °C. Suspensions were finally washed
and re-suspended in 300 μl PBS. Data were acquired on
a BD FACScan flow cytometer (BD Biosciences), 10,000
events were collected for each sample and then analyzed
using the FlowJo software (Tree Star).
Multiple cytokine arrays
Retinas were homogenized in PBS with protease inhibi-
tors (cOmplete, mini, EDTA-free cocktail tablets, Roche)
and centrifuged at 10,000 g for 5 min to remove cellular
debris. Protein concentrations were determined using
total protein assay (Pierce 660 nm Protein Assay Kit,
Thermo Fisher Scientific) and then retinal lysates (150 μg)were incubated with cytokine array membranes (Panel A,
R&D System) according to the manufacturer’s protocol.
Membranes were developed with 800CW streptavidin
(IRDye, LI-COR) for 30 min, and imaged using a LI-COR
Odyssey system. Images were analyzed with Image Studio
Lite 4.0 software (LI-COR). Fluorescence intensities for
each cytokine were averaged and normalized relative to
healthy normal retinas.
Western blotting
To prepare whole retinal lysates, 3 retinas from different
mice were homogenized in 100 μl lysis buffer (9803S,
Cell Signaling Technology) and centrifuged; clear super-
natants were isolated, and protein concentrations were
determined using total protein assay. Aqueous humor/
vitreous samples from 10 eyes were mixed and diluted in
lysis buffer (1:10) with gentle tricheration. Equivalent
proteins of retinal homogenates (120 μg) or aqueous
humor/vitreous mix (60 μg) were separated by electro-
phoresis (Mini-Protean TGX precast protein gels, BIO-
RAD), and transferred onto PVDF membrane (Immun-
Blot, BIO-RAD). After blocking (Odyssey TBS Blocking
Buffer, LI-COR), the membranes were incubated over-
night at 4 °C with primary antibody: rat anti-IL6Rα
monoclonal antibody (1:100, extracellular domain, LS-
C70920, LifeSpan BioSciences); rabbit anti-gp130 poly-
clonal antibody (1:100, M-20, SC-656, Santa Cruz);
rabbit anti-beta actin antibody (1:1000, ab8227, Abcam);
rabbit anti-phospho-STAT3 (Tyr705) antibody (1:500,
#9131, Cell Signaling Technology); rabbit anti-SHP2
antibody (1:100, C-18, sc-280, Santa Cruz); goat anti-
SOCS3 antibody (1:100, M-20, sc-7009, Santa Cruz); or
PathScan® PDGFR activity assay (1:100, phospho-
PDGFR, phospho-SHP2, phospho-Akt, and phospho-
p44/42 Erk1/2 Multiplex Western Detection Cocktail II,
#5304, Cell Signaling Technology). Membranes were
washed, then incubated with 680LT goat anti-rabbit and
800CW goat anti-rat secondary antibodies (both
1:10,000, IRDye, LI-COR) for 30 min at RT. Immunore-
active bands were visualized and analyzed by Odyssey
Imaging System and Image Studio Lite 4.0 software
(LI-COR). More details about anti-IL6Rα and anti-gp130
antibodies used in the current study were shown in
Additional file 1: Table S1.
Statistical analysis
Throughout, data are presented as mean ± standard
error, unless otherwise specified. Multiple-group com-
parisons of flow cytometry data were performed using
two-way ANOVA followed by Tukey Honest Significant
Differences test, and two-group comparisons were
performed using two-sided unpaired Welch Two Sam-
ple t-tests. When data were highly positively skewed,
the distributions were first logarithmically transformed.
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mic transformation, and when minor differences were ob-
served the results of the transformed data were used.
Transformed data were never directly compared to non-
transformed data. Statistical analyses of flow cytometry
data were performed using R version 3.3.1 (R Core Team
2016). The normalized folds in results of multiple cytokine
arrays and Western blots were analyzed using one-way
ANOVA followed by Tukey-Kramer adjustments. Statis-
tical analyses of multiple cytokine arrays and Western
blots were performed using Prism version 5 graphing soft-
ware (GraphPad Software). Throughout, significance levels
are indicated as follows: p < 0.05, * in figures; p < 0.01, **
in figures; and p < 0.001, *** in figures.
Results
Monocyte accumulation after RD
Sodium hyaluronate was injected into the subretinal
space from scleral side, which avoided passage of the
needle through the vitreous and puncturing the retina to
induce RD. Using optical coherence tomography (OCT),
we monitored the location and extent of the retinal de-
tachment (Fig. 1a-c). RD caused a transient, acute retinal
edema that resolved by seven days, consistent with a
previous study [16]. None of the IL6 perturbations (IL6
KO, injection of anti-IL6Rα antibody or anti-gp130 anti-
body) caused retinal atrophy in the area of detachment
(data of retinal thickness not shown). Overall, perturbing
IL6 function did not per se cause dramatic retina atro-
phy, and thus are useful tools for assessing the role of
IL6 in the immune response to RD.
To assess the cellular changes in early intraocular in-
flammation, we prepared retinal flat mounts and cryo-
sections from normal control eyes and RD eyes at one
day following detachment. Ramified microglia were dis-
tributed homogeneously across the retinal surface in
normal control flat mount (Iba1high, Fig. 1d, shown in
green) and had the expected normal ramified appearance
in ganglion cell layer and plexiform layers in cryosec-
tions (Fig. 1e). One day after RD, there was a dramatic
appearance of small round monocytes (CD11bhigh,
Fig. 1d, shown in red). Cryosections further confirmed
CD11bhigh monocytes infiltrating from the vitreous to
inner retina (Additional file 3: Figure S1B), as well as
ameboid Iba1high cells in the outer nuclear layer and
ameboid CD11bhigh macrophages in the subretinal space
(Fig. 1e).
Differential functions for gp130 and IL6Rα in monocyte
recruitment and differentiation
We quantified monocyte and microglia populations after
RD using flow cytometry of dissociated retinal cells
(Fig. 2a-e). As expected, in normal control retinas the
average number of CD11bhigh monocytes was far lessthan the number of IB4high microglia. One day after RD,
the number of monocytes increased more than 20-fold,
and the number of microglia nearly doubled (Fig. 2b).
The total number of immune cells decreased seven days
after RD, primarily due to a relative decrease in
CD11bhigh monocytes (Fig. 2d; compare RD1 with RD7),
though monocyte numbers remained elevated above
normal in all groups (p < 0.001; Fig. 2c, red). We inter-
pret these results to mean that the large influx of infil-
trating monocytes seen on the first day was not
sustained, and that the early-entering monocytes differ-
entiated into microglia, as evidenced by increased num-
bers of cells co-stained for CD11b and Iba1 (Fig. 2f ).
Because IL6 increases in the ocular fluids of RD hu-
man patients [9], we examined the extent of monocyte
infiltration following RD in the absence of IL6 signaling.
In mice lacking IL6 expression entirely (IL6 KO mice),
the number of CD11b + cells one day after RD was re-
duced between IL6 KO RD mice and untreated RD
(wild-type, n = 16 mice) mice (Fig. 2a-d), but this reduc-
tion was not statistically significant (p = 0.926; n = 6
mice). However, there was a significant reduction in
IB4+ cells seven days after detachment in IL6 KO than
wild-type RD retinas (Fig. 2c, green, p < 0.01; n = 6), sug-
gesting that IL6 helps to direct monocyte-to-macrophage
differentiation following extravasation.
To examine the consequences of blocking IL6 signal-
ing in wild-type mice, we performed intravitreal injec-
tion of IL6 receptor antibodies immediately following
retinal detachment. A blocking antibody against the IL6
receptor alpha subunit (anti-IL6Rα) had no effect on the
numbers of CD11b + or IB4+ cells one day (Fig. 2b, n =
16 mice) nor seven days (Fig. 2c, n = 13 mice) after de-
tachment. In contrast, intravitreal injection of a blocking
antibody against the auxiliary subunit β (gp130), which
is shared by several other cytokines, lead to a significant
reduction in CD11b +monocytes compared with un-
treated RD samples (p < 0.01) and RD samples treated
with anti-IL6Rα antibody (p < 0.05) at both one day
(Fig. 2b, n = 13 mice) and seven days after detachment
(Fig. 2c, n = 8 mice, p < 0.05 vs untreated RD7 samples,
n = 14 mice). Intravitreal injection of an isotype control
antibody (n = 3, p < 0.01) or PBS vehicle alone (n = 4, p <
0.001) immediately after retinal detachment did not re-
duce monocyte infiltration like injection of the anti-
gp130 antibody (n = 4; Additional file 3: Figure S1c)
An even more pronounced effect of anti-gp130 treat-
ment was evident on the population of IB4+ cells, resulting
in a doubling of the number of microglia relative to un-
treated RD seven days after detachment (p < 0.001; Fig. 2c).
Together, these results suggest that after RD, circulating
monocytes infiltrate into retina rapidly in a manner that
does not require IL6, but gp130 signaling – presumably
through the action of some other cytokine – promotes
Fig. 1 OCT imaging and immunohistochemistry labeling after retinal
detachment (RD). a Retinal thickness fundus maps and b
corresponding segmented retinal volumes revealed displacement of
the superior retina into the vitreous cavity. In b, location of inner
segment/outer segment border is marked by yellow line. c
Individual OCT b-scans extracted from volumes in b demonstrated
successful RD without any retinal holes. Scale bar = 200 μm. d Retina
flat mounts (bar = 100 μm) and e cryosections (bar = 50 μm) were
used to investigate the spatial distribution of bone marrow-derived
monocytes (CD11bhigh, red round cells) and resident retinal microglia
(Iba1high, green cells) after RD. In normal retina, there were no
monocytes; resident microglia exhibited a resting, ramified-shape,
and they were initially confined to ganglia and plexiform layers. After
the first day of detachment, an increased number of monocytes infil-
trated into untreated RD retina; microglia were activated and
showed amoeboid morphology. Recruited monocytes floated in the
vitreous space, infiltrated the ganglia layer (GCL), inner plexiform
layer, and inner nuclear layer (INL). Both nuclear layers were defined
using DAPI (blue). Activated microglia also became phagocytic, mi-
grated into the outer nuclear layer, and engulfed photoreceptor cell
bodies. Choroid-derived macrophages accumulated in the
subretinal space
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monocytes.
Limited cytokine storm in the retina after RD
To identify cytokine changes induced by the retinal de-
tachment, we subjected homogenates of normal and de-
tached retinas to screening using proteomic arrays
(Table 1). Most cytokines/chemokines showed no change
one day following retinal detachment. Three showed a
significant increase (p < 0.05) relative to normal control
retinas: CCL2 (monocyte chemotactic protein 1), TIMP-1 (tissue inhibitor of metalloproteinase 1), and sICAM-1
(soluble intercellular adhesion molecule-1). CCL2 in-
creased 15-fold in untreated RD1 retinas compared to
normal control retinas (p < 0.001), and was reduced by
all IL6 perturbations, with the IL6 KO being indistin-
guishable from normal control retina (no detachment;
Table 1). This suggests that retinal CCL2 expression is
downstream of IL6. Likewise, TIMP-1, which is secreted
by monocytes/macrophages, was significantly increased
in untreated RD1 retinas compared to normal control
retinas (p < 0.05). In IL6 KO mice, TIMP-1 expression
was dramatically downregulated in retina one day after
RD (p < 0.05) Neither anti-IL6Rα nor anti-gp130 anti-
body treatment with RD altered TIMP-1 expression. Fi-
nally, sICAM-1, a circulating form of ICAM-1
(intercellular adhesion molecule 1) that is highly
expressed in the vitreous of PVR patients [17], showed
sustained, increased sICAM-1 expression for up to seven
days after detachment (p < 0.01). The expression of
sICAM-1 was not affected by any of the treatment
groups (IL6 KO, anti-IL6α, or anti-gp130), suggesting
that sustained retinal expression of sICAM-1 reflects the
intrinsic physical trauma, rather than the immune re-
sponse per se.
Surprisingly, multiple cytokine arrays showed very low
IL6 retinal expression in both normal and detached con-
ditions (Additional file 4: Figure S2a). In addition, IL6Rα,
which is a plasma membrane protein, was undetectable
in retinal samples via Western blot and immunohisto-
chemistry (Additional file 4: Figure S2b-d). Retinal
gp130 expression was detectable (Additional file 3: Fig-
ure S1a), but did not change after RD in any groups
Fig. 2 Quantification of recruited monocytes and resident microglia
with Flow Cytometry. a Representative dot plots for CD11bhigh IB4
low monocytes (top left gate) and CD11blow IB4high resident
microglia (lower right gate) in 5 groups. b After one day, there was
significant monocyte infiltration in all RD groups, as well as an
increased number of microglia (normal = 8 mice; anti-IL6 Rα group
= 16 mice; IL6 KO group = 6 mice). Compared with untreated RD1
retinas (n = 16 mice), only anti-gp130 treated retinas (n = 13 mice)
had fewer monocytes recruited (**p < 0.01). c After seven days, anti-
gp130 still (n = 8 mice) had fewer monocytes compared with un-
treated RD7 retinas (n = 14 mice, *p < 0.05). The other three RD7
groups sustained substantial monocyte infiltration (untreated RD7
***p < 0.001; anti-IL6 Rα =13 mice, ***p < 0.001, IL6 knockout =6
mice ***p < 0.001). Moreover, the number of resident microglia in-
creased significantly in the untreated (***p < 0.001), anti-IL6 Rα(**p <
0.01) and anti-gp130 RD7 retinas (***p < 0.001). Interestingly, anti-
gp130 seemed to boost microglia numbers (compared with un-
treated RD7, ***p < 0.001), while IL6 knockout inhibited this rise in
microglia numbers (**p < 0.01). d Total numbers of microglia and
monocytes in each group. In the untreated and anti-IL6 Rα RD
groups, total immune cells fell after seven days (***p < 0.001 and **
p < 0.01), mainly due to fewer monocytes (***p < 0.001 and * p <
0.05). RD retinas with anti-gp130 treatment had no significant
change in total immune cell numbers, but replenished more micro-
glia (***p < 0.001). In IL6 knockout mice, total immunes cells de-
creased sharply (***p < 0.001), and had the fewest microglia
numbers (**p < 0.01). e Fluorescent microscope image of dissociated
retinal cells used prior to flow cytometry. Retinas were digested,
CD11bhigh monocytes (red round cells) and IB4high microglia (green
cells) were isolated, nuclei were labeled with DAPI (bar = 10 μm). f
Flat mounts (bar = 100 μm) showed that gp130 blocking antibody
was associated with increased numbers of iba1high cells, suggesting
it promoted the differentiation of monocytes (CD11bhigh, red) into
microglia-like macrophages (green) at seven days after RD as evi-
dence by immunohistochemistry co-labeling
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in the retinal expression of IL6 downstream targets
(Fig. 3a), including SOCS3, SHP2, p-STAT3, p-Akt and
p-Erk1/2. IL27, which is highly expressed in mouse ret-
ina and also utilizes the gp130 receptor, also did not sig-
nificantly change after RD (Table 1 and Additional file 4:
Figure S2a). These results suggest that there is little IL6
or gp130 signaling occurring in the retina itself after de-
tachment and instead that the consequences of IL6 KOand IL6 receptor antibody blockades acted directly on
the infiltrating cells.
IL6/IL6 Rα signaling is more active in the aqueous/
vitreous humor than in the retina
Retinal IL6/IL6Rα was undetectable via cytokines arrays,
Western blot and immunohistochemistry in both normal
control and RD retinas (Additional file 4: Figure S2a-d).
Comparable interrogation of aqueous/vitreous humor by
cytokine expression profiling was not possible because
of the very small volumes and relative low target protein
content. However, Western blot analysis of aqueous
humor and vitreous samples showed an increase in
IL6 downstream effectors (Fig. 3b), p-STAT3 (9.26
fold, p < 0.01) and p-Erk1/2 (3.84 fold, p < 0.01) after
retinal detachment (RD1). Anti-gp130 treatment coin-
cident with detachment increased STAT3 phosphoryl-
ation (12.9 fold, p < 0.001) above that of the untreated
RD1 group (p < 0.05). Similarly, the IL6 KO RD1 sam-
ples showed a 4.37-fold upregulation of p-STAT3 (p <
0.05) over the untreated RD1 group (p < 0.01). Both
Table 1 Normalized Cytokines and Chemokines Expression in Detached Retinas
RD 1 day (Mean ± SD) RD 7 days (Mean ± SD)
Untreated (n = 6) Anti-IL6Rα (n = 6) Anti-gp130 (n = 6) IL6 KO (n = 6) Untreated (n = 8) Anti-IL6Rα (n = 6) Anti-gp130 (n = 8) IL6 KO (n = 6)
CXCL1 1.2 ± 0.7 1.2 ± 0.3 0.9 ± 0.3 0.7 ± 0.1 0.5 ± 0.1 0.3 ± 0.2 0.6 ± 0.4 0.6 ± 0.3
CXCL2 1.3 ± 1.3 0.6 ± 0.1 0.3 ± 0.1 0.1 ± 0.0 0.2 ± 0.2 0.2 ± 0.1 0.3 ± 0.2 0.2 ± 0.1
CXCL9 0.6 ± 0.4 1.3 ± 0.5 0.6 ± 0.5 0.3 ± 0.1 0.4 ± 0.4 0.4 ± 0.2 0.4 ± 0.2 0.2 ± 0.1
CXCL10 1.2 ± 0.5 1.7 ± 0.4 1.1 ± 0.3 0.7 ± 0.2 0.7 ± 0.3 0.9 ± 0.9 0.7 ± 0.5 0.4 ± 0.2
CXCL11 0.6 ± 0.3 1.0 ± 0.4 0.6 ± 0.2 0.4 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 0.4 ± 0.3 0.3 ± 0.2
CXCL12 0.8 ± 0.1 0.9 ± 0.3 0.9 ± 0.2 0.7 ± 0.2 0.6 ± 0.3 0.5 ± 0.2 0.7 ± 0.3 0.9 ± 0.1
CXCL13 1.0 ± 0.5 1.0 ± 0.2 1.0 ± 0.1 0.8 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 0.6 ± 0.4 0.5 ± 0.2
CCL1 0.6 ± 0.3 0.8 ± 0.2 0.8 ± 0.1 1.0 ± 0.1 0.5 ± 0.2 0.4 ± 0.1 0.6 ± 0.3 0.6 ± 0.0
CCL2 15.1 ± 6.9 4.4 ± 0.7* 1.7 ± 1.0** 1.2 ± 0.4** 0.7 ± 0.4 1.0 ± 0.8 0.6 ± 0.3 0.5 ± 0.1
CCL3 1.5 ± 1.3 1.5 ± 0.6 0.7 ± 0.5 0.3 ± 0.1 0.3 ± 0.2 0.3 ± 0.1 0.4 ± 0.2 0.4 ± 0.2
CCL4 0.8 ± 0.2 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.5 ± 0.2 0.3 ± 0.1 0.6 ± 0.3 0.8 ± 0.1
CCL5 1.7 ± 1.4 2.1 ± 0.7 1.1 ± 0.5 0.9 ± 0.2 0.6 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.7 ± 0.1
CCL11 0.6 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.5 ± 0.1 0.3 ± 0.1 0.3 ± 0.0 0.5 ± 0.3 0.5 ± 0.1
CCL12 1.1 ± 0.5 1.3 ± 0.3 1.0 ± 0.5 0.7 ± 0.1 0.6 ± 0.1 0.5 ± 0.2 0.6 ± 0.3 0.6 ± 0.4
CCL17 0.8 ± 0.4 0.8 ± 0.1 1.2 ± 0.3 1.4 ± 0.2 0.5 ± 0.2 0.3 ± 0.0 0.6 ± 0.4 0.5 ± 0.4
IL-1α 0.8 ± 0.1 0.7 ± 0.1 1.0 ± 0.1 0.7 ± 0.1 0.5 ± 0.2 0.5 ± 0.4 0.8 ± 0.3 1.0 ± 0.1
IL-1β 0.7 ± 0.4 1.0 ± 0.5 0.6 ± 0.4 0.2 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
IL-1ra 1.9 ± 1.9 1.5 ± 0.2 0.7 ± 0.5 0.5 ± 0.2 0.6 ± 0.2 0.7 ± 0.4 0.6 ± 0.2 0.6 ± 0.1
IL2 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.7 ± 0.2 0.6 ± 0.3 0.4 ± 0.3 0.5 ± 0.2 0.7 ± 0.1
IL-3 0.8 ± 0.3 1.5 ± 0.1 0.8 ± 0.4 0.6 ± 0.2 0.4 ± 0.2 0.3 ± 0.2 0.5 ± 0.4 0.4 ± 0.4
IL-4 0.8 ± 0.5 1.2 ± 0.3 0.6 ± 0.3 0.3 ± 0.1 0.3 ± 0.3 0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.2
IL-5 0.5 ± 0.3 0.8 ± 0.2 0.7 ± 0.2 0.7 ± 0.1 0.5 ± 0.2 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.2
IL-6 0.6 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.8 ± 0.2 0.5 ± 0.1 0.3 ± 0.1 0.7 ± 0.5 0.6 ± 0.5
IL-7 0.6 ± 0.4 0.9 ± 0.3 0.6 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.4 ± 0.3 0.3 ± 0.1
IL-10 0.6 ± 0.2 0.7 ± 0.0 0.6 ± 0.1 0.8 ± 0.2 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.1 0.5 ± 0.0
IL-13 0.7 ± 0.5 1.4 ± 0.6 0.6 ± 0.4 0.2 ± 0.0 0.3 ± 0.2 0.3 ± 0.1 0.3 ± 0.2 0.3 ± 0.0
IL-12 p70 0.5 ± 0.1 0.7 ± 0.1 0.7 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.5 ± 0.4 0.5 ± 0.2
IL-16 0.9 ± 0.6 0.6 ± 0.0 0.7 ± 0.1 0.6 ± 0.1 0.4 ± 0.1 0.3 ± 0.0 0.7 ± 0.5 0.6 ± 0.4
IL-17 0.4 ± 0.3 0.6 ± 0.2 0.4 ± 0.2 0.2 ± 0.1 0.2 ± 0.2 0.2 ± 0.1 0.3 ± 0.3 0.3 ± 0.1
IL-23 0.6 ± 0.2 0.8 ± 0.1 0.6 ± 0.3 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.2 0.5 ± 0.1
IL-27 0.8 ± 0.5 1.6 ± 0.5 0.6 ± 0.7 0.2 ± 0.1 0.3 ± 0.2 0.4 ± 0.1 0.4 ± 0.2 0.3 ± 0.2
G-CSF 0.6 ± 0.4 1.1 ± 0.3 0.9 ± 0.3 0.6 ± 0.0 0.4 ± 0.0 0.3 ± 0.1 0.5 ± 0.2 0.4 ± 0.1
GM-CSF 0.6 ± 0.3 0.9 ± 0.2 1.0 ± 0.2 0.9 ± 0.1 0.5 ± 0.2 0.3 ± 0.0 0.7 ± 0.3 0.6 ± 0.3
M-CSF 0.9 ± 0.5 1.6 ± 0.3 0.9 ± 0.8 0.3 ± 0.1 0.5 ± 0.3 0.5 ± 0.3 0.6 ± 0.4 0.4 ± 0.4
sICAM-1 2.3 ± 0.7 2.3 ± 0.3 2.2 ± 0.3 1.8 ± 1.0 2.7 ± 0.1 2.6 ± 0.5 2.3 ± 0.4 2.0 ± 0.6
IFN-γ 0.7 ± 0.4 1.3 ± 0.8 0.7 ± 0.4 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.2 0.6 ± 0.1
TIMP-1 3.9 ± 3.9 3.6 ± 1.1 1.3 ± 1.5 0.5 ± 0.2* 1.2 ± 1.6 1.6 ± 1.9 0.9 ± 0.7 0.6 ± 0.7
TNF-a 0.6 ± 0.3 0.8 ± 0.2 0.9 ± 0.2 1.1 ± 0.0 0.6 ± 0.3 0.5 ± 0.2 0.8 ± 0.3 0.9 ± 0.1
TREM-1 1.3 ± 0.7 2.1 ± 0.6 0.9 ± 0.6 0.5 ± 0.0 0.5 ± 0.3 0.5 ± 0.2 0.5 ± 0.2 0.4 ± 0.1
C5/C5a 0.6 ± 0.4 0.8 ± 0.2 0.5 ± 0.3 0.4 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.4 ± 0.3 0.2 ± 0.3
Fluorescence values of multiple arrays were normalized to normal control (not detachment) retinas, shown in ratios and statistically compared with untreated RD
retina. *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 3 (See legend on next page.)
Wang et al. Journal of Neuroinflammation  (2017) 14:121 Page 8 of 14anti-gp130 treated (p < 0.01) and loss of IL6 expres-
sion (IL6 KO mice; p < 0.05) prevented the RD1-
induced increase in p-ERK1/2. Together (Fig. 4), these
results suggest that IL6 signaling in the aqueous/vitreous occurs via gp130, and that anti-gp130 treat-
ment targeted monocytes in the vitreous, not in the
retina, causing an upregulation of p-STAT3 and an
inhibition of p-Erk1/2 in those cells.
(See figure on previous page.)
Fig. 3 Protein expression of IL6/gp130 signaling pathway in mice one day after RD. a In retinas (n = 6 mice for each group), gp130 expression
increased non-significantly after RD and was consistently expressed in all treatment groups. In contrast, membrane-bound IL6Rα was undetectable
(note very high IL6Rα expression in liver). The key regulatory proteins of IL6 signaling, SOCS3, SHP2, p-STAT3, p-Akt and p-Erk1/2, all showed no
significant changes in the retina one day after RD (one-way ANOVA, Tukey’s test). b In aqueous/vitreous humor samples (n = 10 mice for each
group), p-STAT3 was up-regulated 9-fold (compared with normal, ** p < 0.01), anti-gp130 further promoted this phosphorylation (13-fold higher
than normal, *** p < 0.001; compared with untreated RD1 group, * p < 0.05); while IL6 KO weakened this upregulation (4-fold, compared with nor-
mal, * p < 0.05; compared with untreated RD1 group, ** p < 0.01). p-Erk1/2 was also up-regulated after RD (4-fold, compared with normal, ** p <
0.01), while anti-gp130 (0.96 fold, compared with untreated RD1 group, ** p < 0.01) and IL6 KO (1.98 fold, compared with untreated RD1 group, *
p < 0.05) both inhibited p-Erk1/2 activation. Note: the intensities of SOCS3, SHP2, p-STAT3, p-Akt and p-Erk1/2 bands in all 3 detached groups
were normalized to their intensities of normal group, and then the normalized folds were analyzed using one-way ANOVA followed by
Tukey-Kramer adjustments
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Vitreal monocytes as the predominant source of IL6
following RD
High IL6 levels have been correlated with the severity of
RD and the incidence of PVR complications [8]. In our
experiments, retinal IL6 protein expression was un-
detectable following retinal detachment (Table 1; Add-
itional file 4: Figure S2a), which is consistent with
RNAseq data showing low IL6 gene expression [18].
These results suggest that although high levels of IL6 are
evident in human samples of aqueous humor [7], vitre-
ous [9] and subretinal fluid [7–9], it is apparently not se-
creted by the retina, but rather by invasive cells [10] in
the vitreous.
The identity of the cells secreting IL6 has been am-
biguous. In our mouse model of RD, hemi-retinal de-
tachment was induced without any retinal holes,
obviating the migration of subretinal macrophages and
RPE cells into vitreous and retina surface and thus re-
moving these cells as likely sources of IL6. Instead, our
study shows that bone marrow-derived monocytes rap-
idly infiltrate the vitreous (Additional file 3: Figure S1b)
within one day after detachment, and likely are the
source of IL6 rather than merely the cells responding to
IL6.
Clinical studies have demonstrated that epiretinal
membranes (ERM) from PVR patients had the greatest
density of immune cells compared with those with suc-
cessful retinal detachment repair, those with proliferative
diabetic retinopathy, or those with idiopathic ERM pa-
tients [19]. Thus, inhibiting monocyte extravasation and
their IL6 secretion in the early stages of RD may reduce
inflammation and the risk of PVR development in RD
patients. Interestingly, our Western blotting results
failed to detect membrane-bound IL6Rα protein both in
the retina (Fig. 3a) and aqueous/vitreous humor (Add-
itional file 4: Figure S2 b,c) before or after RD, consistent
with previous reports of very low IL6Rα gene expression
in mouse retina [18] but higher levels of soluble IL6Rα
in vitreous humor [20] of PVR patients. This suggests
that the IL6 secreted by monocytes further impinges
upon monocytes or blood vessels via IL6 trans-signaling,rather than retinal neurons via classic IL6 signaling.
Given the low IL6Rα expression in the retina, it is not
too surprising that there were also no significant changes
in key regulatory proteins downstream of IL6 signaling
in the retina, including p-STAT3, p-Akt and p-Erk1/2
(Fig. 3a). In contrast, aqueous/vitreous humor samples
from RD mice showed strong upregulation of p-STAT3
(9-fold) and p-Erk1/2 (4-fold). These results suggest the
view that the aqueous and vitreous humor, rather than
the retina or subretinal space, are the key compartments
where IL6/gp130 signaling is regulated in RD.
The role of the retina in retinal detachment
Our cytokine array results revealed a dramatic (15-fold)
increase in retinal CCL2 levels within one day of RD
(Table 1). CCL2, also known as monocyte chemoattract-
ant protein 1 (MCP1), is the key chemokine regulating
migration and infiltration of monocytes/macrophages
[21]. In the rat RD model, CCL2 likewise increased rap-
idly and subsided after three days [22], driving influx of
CCR2+ monocytes [23]. The primary intraocular source
of CCL2 after RD is thought to be Müller glia [24, 25],
and CCL2 blockade greatly reduced macrophage/micro-
glia infiltration and photoreceptor apoptosis [24]. Strong
correlation between IL6 and CCL2 levels has been found
in most human vitreoretinal diseases [26–28], consistent
with both of these chemokines being temporally associ-
ated with monocyte infiltration. However, we also found
that loss of IL6 or blockade of each of its two receptors
all inhibited the RD induced increase in retinal CCL2
levels (Table 1). Since neither IL6 nor IL6Rα are
expressed at detectable levels in the retina, our results
suggest that gp130 mechanistically lies between
monocyte-secreted IL6 in the vitreous and the induction
of CCL2 expression in the Müller glia.
We also observed a ~4-fold increase in the expression
of retinal TIMP-1 within one day of RD (Table 1, p <
0.05). The tissue inhibitors of metalloproteinases
(TIMPs) are specific inhibitors of the Matrix metallopro-
teinases (MMPs). Like CCL2, TIMP-1 levels also correl-
ate significantly with IL6 levels in PVR patients [9], and
are found in vitreous and subretinal fluid of RD patients
Fig. 4 Model summary of intraocular IL6 and gp130 signaling. a One day after RD, retina secretes CCL2, sICAM-1 and TIMP-1. Bone marrow
derived-monocytes are recruited into the vitreous. Active monocytes upregulate p-STAT3 and p-Erk1/2. However, anti-gp130 treatment inhibits
CCL2 secretion and monocyte recruitment, by strengthening p-STAT3 and downregulating p-Erk1/2 in vitreous monocytes after RD. IL6 knockout
mice inhibit CCL2 and TIMP-1 secretion, weaken p-STAT3 and p-Erk1/2 activation after RD. b Seven cytokines signal via gp130, but most of the
them and their co-receptors have very weak or undetectable expression (shown by dotted line) in mouse retina, including IL6 and receptor IL6Rα.
In the retina, gp130 only signals through IL11/IL11Rα (shown by solid line) but IL11 is not changed after RD. This can explain why there was no
IL6/IL6Rα protein expression in retina and why there were no significant changes of gp130, p-STAT3, p-Akt and p-Erk1/2 in retina after RD in our
study. Despite high IL6 in vitreous (secreted by monocytes), the retinal IL6/IL6Rα signaling is silent. Therefore, anti-gp130, not anti-IL6 or anti-
IL6Rα, may be beneficial to retina, by intervening early inflammation after RD
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ment [9, 28]. In previous mouse studies, TIMP-1 was
upregulated for two weeks following RD [29], suggesting
a sustained response to damage or an involvement in
retinal healing. In our studies, blocking IL6 receptorsdid not affect TIMP-1 expression one day after RD (p >
0.05), though complete loss of IL6 (IL6 KO) drastically
reduced TIMP-1 expression (Table 1). We infer that
high IL6 levels promote early stage M1 macrophage
polarization, while anti-IL6 may promote M2 macrophage
Wang et al. Journal of Neuroinflammation  (2017) 14:121 Page 11 of 14polarization, the latter of which downregulates TIMP-1
expression [30] in the later stage of inflammation.
Good or Bad? The role of IL6 signaling depends on the
gp130 cytokine family
In our model of retinal detachment, IL6 KO mice did
not show any fewer infiltrated monocytes after RD
(Fig. 2b, c). This suggests that IL6 per se is not the mas-
ter cytokine initiating inflammation for the retina after
detachment. Thus, RD patients are unlikely to benefit
from humanized monoclonal antibody (mAb) against
IL6 only.
Blocking the downstream consequences of IL6, how-
ever, proved to have interesting and profound conse-
quences for monocyte infiltration. A monoclonal
blocking antibody against gp130 reduced monocyte re-
cruitment (Fig. 2a), seemed to promote monocyte differ-
entiation into microglia-like macrophages (Fig. 2b-d),
and reduced retinal CCL2 secretion (Table 1). Anti-
gp130 therapy also upregulated p-STAT3 and downregu-
lated p-Erk1/2 in vitreous samples after RD (Fig. 3b). Be-
cause p-STAT3 upregulation and p-Erk1/2 inhibition
have protective effects for photoreceptors [31] and RPE
survival [32], these findings suggest that the anti-gp130
antibody is beneficial to detached retina. Similar results
in a model of experimental colitis using gp130 (757 F/F)
mice [33] supports the notion that gp130 is a pivotal
molecule acting downstream of IL6 to more specifically
control macrophage fate and tissue repair. Notably, these
consequences of blocking downstream IL6 signaling was
specific for gp130; blocking the canonical IL6 receptor,
IL6Rα, had no effect on monocyte infiltration and the
cytokine storm.
Working model of distinct IL6 and gp130 signaling at the
retina-vitreous interface
There are seven known cytokines that signal via gp130
(Fig. 4): IL6, IL11, IL27, CT-1, LIF, CNTF, and OSM.
Gene sequencing of the gp130 cytokine family in mouse
retina has shown [18] that there is very low gene expres-
sion of IL6, IL11, LIF or OSM (Fig. 4b, shown by dotted
line) in retinal photoreceptors, horizontal cells, bipolar
cells, amacrine cells, ganglion cell layer, and microglia.
This means within the gp130 cytokine family, retina only
has the intrinsic capacity for IL27, CT-1, and CNTF sig-
naling (Fig. 4b, shown by solid line); the other four cyto-
kines are exogenous and must be secreted by other cells
(e.g., IL6 secreted by infiltrated monocytes). Many of the
co-receptors that dimerize with the gp130 receptor to
support cytokine signaling are also weakly expressed in
the retina (Fig. 4b, dotted lines). Genes of IL6Ra, IL27
receptor (WSX-1), LIFR, CNTFR and OSMR are
expressed at undetectable levels [18]. Only IL11 receptor
α1 (IL11Rα1) and gp130 genes are highly expressed [18].A comprehensive review of the gp130 cytokine family in
mouse and human retina before and after RD [8, 10, 25,
27, 34–73] is shown in Additional file 2: Table S2.
Thus, the only cytokine/receptor combination
expressed in the retina to support gp130 signaling is via
IL11/IL11Rα. We predict that the anti-gp130 antibody
inhibited CCL2 release from Müller glia using this sig-
naling pathway. However, because IL11 is not signifi-
cantly upregulated in the subretinal fluid of PVR [8]
patients or gliotic human retina [25], we infer that IL11
is not associated with PVR development. This model
thus explains why there was weak retinal IL6/IL6Rα ex-
pression and why there were no significant changes in
gp130, p-STAT3, p-Akt and p-Erk1/2 levels after RD:
the weak signaling pathway of gp130 in retina is due to
negligible expression of cytokines and receptors.
Conclusions
In summary, we found that following retinal detach-
ment, monocyte infiltration into the vitreous and vitreo-
retinal interface is rapid, and sets off a cascade of down-
stream cytokine events that further escalates immune re-
sponse, like retinal CCL2 expression. The infiltrated
monocytes release IL6, which promotes signaling
through gp130 to control macrophage polarization. In
humans, a clinical study revealed that intravitreal injec-
tion of steroids failed to decrease IL6 secretion in RD
patients [53]. Our results in the mouse suggest that a
more specific, cytokine-targeted therapy for RD patients
may be more effective. So far, there are several FDA-
approved monoclonal antibodies against IL6 signaling,
including Clazakizumab and Olokizumab (anti-IL6) and
Tocilizumab (anti-IL6Rα), yet none of them are likely to
reduce RD-associated inflammation based on our re-
sults. In contrast, anti-gp130 may be a promising thera-
peutic strategy reduce early inflammation after RD when
immediate re-attachment is not possible.
Additional files
Additional file 1 Table S1. Antibodies used in the current study. (PDF
237 kb)
Additional file 2 Table S2. Ocular Expression of the gp130 Receptor
Cytokine Family in Normal and Detached Retina of Mouse and Human.
(PDF 219 kb)
Additional file 3 Figure S1. gp130 expression following acute retinal
detachment (RD) and isotype control experiment. (A) The gp130
expression (red) and Müller cells (CRALBP, green) in normal and detached
retinas (bar = 50 μm). Two nuclei layers were stained with DAPI (blue).
Retinal gp130 expression was initially confined to outer nuclear layer
(ONL) in normal retina, and extended into the inner nuclear layer and
monocytes in vitreous humor after RD. (B) Recruited monocytes floated
in the vitreous space one day after RD (bar = 10 μm). CD11b (green) and
membrane-bound gp130 (red) co-stained in monocytes. Nuclei were
stained with DAPI (blue). (C) Additional evidence to support the thera-
peutic effect of anti-gp130 antibody. Intravitreal injection of an isotype
control antibody (n = 3, p < 0.01) or PBS vehicle alone (n = 4, p < 0.001)
Wang et al. Journal of Neuroinflammation  (2017) 14:121 Page 12 of 14immediately after RD did not reduce monocyte infiltration like injection
of the anti-gp130 antibody (n = 4). (JPG 9157 kb)
Additional file 4 Figure S2. IL6/IL6Rα expression before and after acute
retinal detachment. (A) Multiple cytokines arrays showed very low IL6
expression in either normal or detached retinas. Most cytokines/
chemokines showed no change one day following RD, while CCL2 and
TIMP-1 are found to be strongly related to IL6 signaling. They both signifi-
cantly increased in untreated RD1 retinas compared to normal retinas,
while detached retinas of IL6 KO mice showed downregulation of CCL2
and TIMP-1. Interestingly, IL27, which shares the same receptor gp130
with IL6 signaling, did not significantly change after RD. IL27 expression
seemed weaker in IL6 KO retinas after RD, but didn’t have significant dif-
ference (one-way ANOVA, Tukey-Kramer adjustments). (B) The
membrane-bound IL6 receptor α (IL6R α) was undetectable in the retina
via western blot, while the IL6 receptor β (gp130) has stable expression
in normal and IL6 KO retinas. (C) One day after RD, the gp130 expression
was detected and increased in aqueous humor/vitreous via western blot,
while membrane-bound IL6R α was still undetectable. (D) We verified
IL6Rα protein expression by immunohistochemistry in normal retina and
detached retina using 3 different primary antibodies and isotype control.
They all showed nonspecific binding and low expression of IL6Rα. (JPG
8267 kb)
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